Tirofiban hydrochloride is under clinical development by Merck & Co and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Tirofiban hydrochloride’s likelihood of approval (LoA) and phase transition for Unstable Angina took place on 08 Nov 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tirofiban hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Tirofiban hydrochloride overview

Tirofiban hydrochloride (Aggrastat / Agrastat) is a phenylpropanoic acid derivative acts as an anti-platelet and also as a fibrinolytic agent. It is formulated as solution and concentrate solution for intravenous route of administration. Tirofiban hydrochloride is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).  It is under development for percutaneous coronary intervention, acute coronary syndrome, unstable angina and myocardial infarction. It is administered by parenteral route. It is under development for subarachnoid hemorrhage and aneurysm. It is administered by intravenous route.

The transdermal formulation of Tirofiban hydrochloride (Aggraderm) was under development for acute coronary syndrome.

Merck & Co overview

Merck & Co (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

Quick View Tirofiban hydrochloride LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Tirofiban hydrochloride
Administration Pathway
  • Intravenous
  • Parenteral
  • Transdermal
Therapeutic Areas
  • Cardiovascular
Key Developers
  • Sponsor Company: Merck & Co
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.